Knight Therapeutics (TSE:GUD) Hits New 1-Year High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD) shares reached a new 52-week high during mid-day trading on Monday . The stock traded as high as C$9.51 and last traded at C$9.46, with a volume of 62054 shares traded. The stock had previously closed at C$9.48.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$9.50 target price on Knight Therapeutics and gave the stock a “buy” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of C$9.50.

Knight Therapeutics Stock Up 0.2%

The company has a quick ratio of 1.79, a current ratio of 2.32 and a debt-to-equity ratio of 8.86. The firm has a 50 day simple moving average of C$8.19 and a 200-day simple moving average of C$6.90. The stock has a market cap of C$914.05 million, a P/E ratio of 155.17, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.14.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings data on Thursday, May 7th. The company reported C$0.13 earnings per share (EPS) for the quarter. The firm had revenue of C$147.59 million for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%. On average, equities research analysts forecast that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.